Successful Treatment of Generalized Pustular Psoriasis With Spesolimab in Two Young Children

Spesolimab is an IL‐36 receptor monoclonal antibody antagonist approved for generalized pustular psoriasis in patients 12 years and older. While it has demonstrated promising results in this population, there is limited literature exploring spesolimab efficacy and dosing in younger patients. We report the cases of a 5‐year‐old female with generalized pustular psoriasis in the setting of autosomal recessive deficiency of interleukin‐36 receptor antagonist (DITRA) as well as a 6‐year‐old female with generalized pustular psoriasis of unknown genetic status, both successfully treated with spesolimab.